Actavis, which held informal conversations with Allergan in recent months about a possible combination, would like to take a hard look at buying the company and could reach out to its management team as soon as this week to reiterate its interest, one of the sources said. There has been no formal engagement between the two companies yet, the sources said, asking not to be named because the matter is not public.